COVID-19 and the Surveillance, Epidemiology, and End Results Program: Future considerations for skin cancer research
- PMID: 33832860
- PMCID: PMC8011318
- DOI: 10.1016/j.bjps.2021.03.044
COVID-19 and the Surveillance, Epidemiology, and End Results Program: Future considerations for skin cancer research
Conflict of interest statement
Declaration of Competing Interest The authors report no conflicts of interest relevant to this work
Similar articles
-
Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview.Urol Oncol. 2012 Mar-Apr;30(2):126-32. doi: 10.1016/j.urolonc.2009.11.005. Epub 2010 Apr 3. Urol Oncol. 2012. PMID: 20363162 Review.
-
Limitations and biases of the Surveillance, Epidemiology, and End Results database.Curr Probl Cancer. 2012 Jul-Aug;36(4):216-24. doi: 10.1016/j.currproblcancer.2012.03.011. Epub 2012 Apr 4. Curr Probl Cancer. 2012. PMID: 22481009 No abstract available.
-
Hospital information systems and clinical cancer research.Cancer Invest. 2004;22(2):326-7. doi: 10.1081/cnv-120030222. Cancer Invest. 2004. PMID: 15199616 No abstract available.
-
Serological tests for COVID-19.Med J Aust. 2020 Nov;213(9):397-399.e1. doi: 10.5694/mja2.50766. Epub 2020 Sep 6. Med J Aust. 2020. PMID: 32892381 No abstract available.
-
The future of research that promotes cancer screening.Cancer. 2004 Sep 1;101(5 Suppl):1251-9. doi: 10.1002/cncr.20510. Cancer. 2004. PMID: 15316910 Review.
References
-
- Tripathi R., Mazmudar R.S., Knusel K.D., Bordeaux J.S., Scott J.F. Big data in dermatology: publicly available health care databases for population health research. J Am Acad Dermatol. 2020;83(5):1546–1556. - PubMed
-
- Surveillance, Epidemiology, and End Results Program. National Cancer Institute. https://seer.cancer.gov/. Accessed January 27, 2021.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical